|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Homeobox A9 (HOXA9) is an oncogene in leukemia and has been implicated in CRC pathology, although its role in disease etiology remains obscure at best.
|
31099823 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the function of Meningioma 1 (MN1), a cofactor of HOXA9 and MEIS1, in human and murine MLL-rearranged leukemia by CRISPR-Cas9 mediated deletion of MN1.
|
31413090 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeting JMJD1C-mediated metabolism via pharmacologic inhibition of glycolysis and oxidative phosphorylation led to ATP depletion, induced necrosis/apoptosis and decreased tumor growth in vivo in leukemias co-expressing JMJD1C and HOXA9.
|
30622285 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a murine bone marrow transplantation model, mice transplanted with cells overexpressing Ednra and Hoxa9 succumbed to leukemia significantly earlier than mice transplanted with cells overexpressing Hoxa9 only.
|
30384975 |
2018 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> Using the gene expression profiling of TCGA and E-MTAB-3444 datasets, we screened for high co-expression of PBX3 and HOXA9 in NPMc+ leukemia patients.
|
30214626 |
2018 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MLL-AF9 is one such rearrangement that recruits the lysine methyltransferase, human disruptor of telomere silencing 1-like (DOT1L) and lysine specific demethylase 1 (LSD1), resulting in elevated expression of the Homeobox protein A9 (HOXA9), and leukemia.
|
29972300 |
2018 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of mutant JAK3 and HOXA9 led to a rapid development of leukemia originating from multipotent or lymphoid-committed progenitors, with a significant decrease in disease latency compared with JAK3 or HOXA9 alone.
|
29496663 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcription of the HOXA9 and HOXA10 genes is enhanced in hematopoietic stem and progenitor cells in these leukemias.
|
29459712 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interaction of HOXA9/MEIS1/PBX3 is responsible for hematopoietic system transformation in MLL-rearranged (MLL-r) leukemia.
|
28411381 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant fusion proteins involving the MLL histone methyltransferase (HMT) lead to recruitment of DOT1L, to a multi-protein complex resulting in aberrant methylation of histone H3 lysine 79 at MLL target genes, and ultimately enhanced expression of critical genes for hematopoietic differentiation, including HOXA9 and MEIS1, and as such defines the established mechanism for leukemogenesis in MLL-rearrangement (MLL-r) leukemias.
|
28229434 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic characterization of NA9-induced phenotypes suggested interference with PVR (Flt1-4 RTK homolog) signaling, which is similar to functional interactions observed in mammals between Flt3 and HOXA9 in leukemia.
|
27838340 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we elucidated the direct correlation between HoxA9 expression and progression of leukaemia using 2 different types of leukaemia cells HL-60 and MOLT-3.
|
28961318 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, Syk inhibition disrupts the identified regulatory loop, prolonging survival of mice with Hoxa9/Meis1-driven leukemia.
|
28399410 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To define the role of Flt3 in AML with high Hoxa9/Meis1, we treated mice with Hoxa9/Meis1-induced AML with the Flt3 inhibitor AC220, used an Flt3-ligand (FL-/-) knockout model, and investigated whether overexpression of Flt3 could induce leukemia together with overexpression of Hoxa9.
|
27617578 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data indicate that MLL is crucial for NUP98-HOXA9 leukemia initiation.
|
28210005 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increasing efforts are being made to identify both the critical cofactors and target genes required for maintaining transformation in HOXA9-overexpressing leukemias.
|
26028034 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although MEIS1 alone has only a moderate effect on cell proliferation in vitro, it is essential for the development of HOXA9-induced leukemia in vivo.
|
27018596 |
2016 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Understanding the mechanisms regulating the expression and activity of HOXA9, along with its critical downstream targets, shows promise for the development of more selective and effective leukemia therapies.
|
27258906 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, kinetics and severity of disease in transplantation assays indicated that Pbx3/Meis1 dimers are rate-limiting factors for Hoxa9-induced leukemia.
|
25911551 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mixed-lineage leukemia (MLL) maintains the expression of cellular memory genes during development, while leukemic MLL fusion proteins aberrantly maintain expression of hematopoietic stem cell program genes such as HOXA9 to cause leukemia.
|
24465000 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data establish microRNA as functional effectors of endogenous HOXA9 and HOX-based leukemia oncoproteins, provide a concise in vivo platform to test RNA therapeutics, and suggest therapeutic value for microRNA antagonists in AML.
|
24334453 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although high expression of Hoxa9 in MLL fusion leukemia is supposed to be responsible for the recruitment of EZH2, our data also suggest that there may be some other mechanisms independent of Hoxa9 activation to suppress p16 expression, because expression levels of Hoxa9 and p16 were not inversely related between MLL/ENL and Hoxa9/Meis1 transduced cells.
|
24612037 |
2014 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prdm16, a transcription factor associated with human acute myeloid leukemia, was markedly repressed by HOXB4 but upregulated by HOXA9 and HOXA10, suggesting that Prdm16 downregulation was involved in preventing leukemia in HOXB4 transplanted mice.
|
25082879 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mixed lineage leukemia (MLL) fusion proteins directly activate the expression of key downstream genes such as MEIS1, HOXA9 to drive an aggressive form of human leukemia.
|
24445817 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quantitative-reverse transcriptase polymerase chain reaction analysis demonstrated a strong repression of B cell specific genes in these E2A-PBX1/Hoxa9 leukemias in addition to Flt3 activation, indicating inhibition of B cell differentiation in combination with enhanced proliferation.
|
23996689 |
2014 |